We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-4.33%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.5B
AUM Growth
-$794M
Cap. Flow
+$217M
Cap. Flow %
1.89%
Top 10 Hldgs %
81.68%
Holding
128
New
8
Increased
22
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$146M
2
ABLX
Ablynx NV
ABLX
+$94M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$73M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$54.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$45M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$170M
2
AKAO
Achaogen Inc
AKAO
+$47.2M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$22.2M
4
EXEL icon
Exelixis
EXEL
+$15.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 93.21%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.3B
$3.24B 28.1%
34,230,523
+200
+0% +$20.9K
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$2.45B 21.2%
45,725,556
– –
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.02B 8.87%
8,553,864
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.46B
$820M 7.11%
27,228,338
+1,408,570
+5% +$45M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12B
$676M 5.86%
7,583,084
+1,677,411
+28% +$146M
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$471M 4.09%
13,781,102
+622
+0% +$19.8K
ONC
7
BeOne Medicines Ltd
ONC
$34.1B
$376M 3.26%
3,849,231
-49,200
-1% -$4.5M
DBVT
8
DBV Technologies
DBVT
$798M
$136M 1.17%
550,956
– –
NGNE icon
9
Neurogene
NGNE
$643M
$129M 1.11%
546,708
– –
ASND icon
10
Ascendis Pharma A/S
ASND
$16.7B
$105M 0.91%
2,618,818
+269,978
+11% +$9.82M
ABLX
11
DELISTED
Ablynx NV
ABLX
$104M 0.9%
+4,161,118
New +$94M
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$102M 0.88%
616,514
+211,029
+52% +$20.5M
AMRN
13
Amarin Corp
AMRN
$294M
$90.9M 0.79%
1,133,475
– –
AVXS
14
DELISTED
AveXis, Inc. Common Stock
AVXS
$85.8M 0.74%
775,000
– –
NBIX icon
15
Neurocrine Biosciences
NBIX
$18.3B
$77.9M 0.68%
1,004,624
+387,942
+63% +$26.5M
ARRY
16
DELISTED
Array Biopharma Inc
ARRY
$72.4M 0.63%
5,656,196
+442,668
+8% +$5.04M
ONCE
17
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$71.2M 0.62%
1,384,130
– –
BCRX icon
18
BioCryst Pharmaceuticals
BCRX
$2.44B
$68.7M 0.6%
13,997,172
– –
PHXM
19
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$68M 0.59%
+309,007
New +$73M
NVTA
20
DELISTED
Invitae Corporation
NVTA
$66.2M 0.57%
7,288,300
– –
ARGX icon
21
argenx
ARGX
$55.2B
$60.7M 0.53%
961,754
+861,754
+862% +$28.2M
RYTM icon
22
Rhythm Pharmaceuticals
RYTM
$7.38B
$59.5M 0.52%
+2,049,020
New +$54.2M
MDGL icon
23
Madrigal Pharmaceuticals
MDGL
$12.5B
$56.5M 0.49%
615,684
+557,922
+966% +$31.9M
HRTX icon
24
Heron Therapeutics
HRTX
$92.6M
$55.4M 0.48%
3,060,641
+272,649
+10% +$4.45M
MRTX
25
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$46.5M 0.4%
2,549,461
+280,263
+12% +$4.35M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Baker Bros. Advisors held 128 positions worth $11.5B, down 6.4% from $12.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors's Q4 2017 filing shows 8 new, 22 increased, 12 reduced and 5 closed positions. Its largest new stake was Ablynx NV: 4,161,118 shares worth $104M. The largest sale was Advanced Accelerator Applications S.A., an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q4 2017 buy was Ablynx NV: 4,161,118 shares worth $104M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $146M increase.
  • Baker Bros. Advisors's biggest Q4 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $170M.
  • Baker Bros. Advisors fully exited NeuroDerm Ltd. Ordinary Shares in Q4 2017, selling an estimated $22.2M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $11.5B portfolio in Q4 2017.
  • Baker Bros. Advisors opened 8 new positions and closed 5 in Q4 2017.
  • Baker Bros. Advisors's portfolio value fell 6.4% quarter-over-quarter to $11.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.